Rizwan Romee MD

Hematology•Boston, MA

Hematologic Oncology

Associate Professor, Harvard Medical School, Dana Farber Cancer Institute

Join to View Full Profile

450 Brookline AveBoston, MA 02215
Phone+1 617-632-5138

Summary

I am a cancer immunologist and the research focus of my lab is to engineer NK cells for enhanced targeting of advanced malignancies.

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Blood & Bone Marrow Transplant, 2011 - 2012
University of MinnesotaFellowship, Hematology and Medical Oncology, 2008 - 2011
University of MinnesotaResidency, Internal Medicine, 2005 - 2008
Government Medical College SrinagarClass of 2003

Certifications & Licensure

MA State Medical License 2018 - 2027
MO State Medical License 2011 - 2019
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

ASH Scholar Award (faculty-clinical) American Society of Hematology, 2015
ASCO Career Development Award (faculty) 2015
ICTS Translational Research Award Washington University, 2014
Barnes Jewish Hospital Foundation Team Science Award Barnes Jewish Hospital, 2014
Siteman Cancer Center Research & Development Award Siteman Cancer Center, 2013
CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Join now to see all

Clinical Trials

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT Start of enrollment: 2013 Nov 11
Completed
Phase 1, Phase 2
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Start of enrollment: 2014 Aug 11
Terminated
Phase 1, Phase 2
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma Start of enrollment: 2014 Mar 19
Completed
Phase 2
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2014 Feb 28
Terminated
Phase 1
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
Completed
Phase 2
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation Start of enrollment: 2015 Jan 20
Terminated
Phase 2
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
Completed
Phase 1
Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation Start of enrollment: 2016 Jun 27
Terminated
Phase 1
Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation Start of enrollment: 2017 Jan 30
RECRUITING
PHASE2
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant Start of enrollment: 2017 Oct 23
RECRUITING
PHASE1, PHASE2
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation Start of enrollment: 2019 Aug 31
ACTIVE_NOT_RECRUITING
PHASE1
CIML NK Cells With Venetoclax for AML Start of enrollment: 2024 Feb 20
RECRUITING
PHASE1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gra...
Cindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, Rizwan Romee, Navneet S Majhail
Transplantation and Cellular Therapy. 2025-03-01
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.
Roman M Shapiro, Michal Sheffer, Matthew A Booker, Michael Y Tolstorukov, Grace C Birch
Journal of Hematology & Oncology. 2025-02-14
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.
Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, Ting Wu, Nicholas Tsakmaklis
Nature Communications. 2025-02-10

Journal Articles

The European Society for Blood and Marrow Transplantation (EBMT) Consensus Recommendations for Donor Selection in Haploidentical Hematopoietic Cell Transplantation
Leo Luznik, Karen Ballen, Asad Bashey, Hillard M Lazarus, Bipin N Savani, Rizwan Romee, Ephraim J Fuchs, Nature
Virescent Tongue
Rizwan Romee, Meagan Jacoby, Annals of Hematology
Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation
M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights fro...
Rizwan Romee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
Rizwan Romee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
Rizwan Romee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Hematopoietic Cell Transplantation Donor Selection Reimagined: KIR-KIR Ligand Interactions and a Formalized Donor Risk Index Effective at Predicting Survival
Rizwan Romee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation
Rizwan Romee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Study Results of CX-01, an Inhibitor of CXCL12/CXCR4, and Azacitidine for the Treatment of Hypomethylating Agent Refractory AML and MDSClinically Relevant Abst...
Rizwan Romee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leu...
Rizwan Romee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Press Mentions

CAR Natural Killer Cell Therapy Shows Promise in B-cell LymphomasJanuary 13th, 2025
NK Cells Show Promise Against Common Ovarian CancerJuly 13th, 2024
XNK Therapeutics Strengthens Its Scientific Network with Two More AdvisorsDecember 19th, 2021
Join now to see all